Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has issued a cleansing notice related to the release of convertible notes, securing up to US$27 million through an agreement with Obsidian Global GP LLC. This financial move is set to increase the company’s cash reserves by an initial US$7 million, potentially impacting its operational capabilities and market positioning by enhancing liquidity and financial flexibility.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing and commercializing therapies for unmet medical needs. The company is listed on the Australian Securities Exchange (ASX) under the ticker PAR.
YTD Price Performance: 24.00%
Average Trading Volume: 922,981
Technical Sentiment Signal: Buy
Current Market Cap: A$184.8M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.